Edesa Biotech’s ARDS Drug Chosen for US Trial
Company Announcements

Edesa Biotech’s ARDS Drug Chosen for US Trial

Edesa Biotech (EDSA) has released an update.

Edesa Biotech’s novel drug, paridiprubart, has been selected by the U.S. Biomedical Advanced Research and Development Authority (BARDA) for a Phase 2 trial in patients with acute respiratory distress syndrome (ARDS) from various causes. The drug aims to modulate the immune system’s response to public health threats and has shown promise in reducing mortality in ARDS patients during a previous study. This effort is part of a broader public-private initiative to develop therapeutics that are ready for rapid deployment in emergencies, including pandemics and biodefense situations.

For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskEdesa Biotech Gains CEO’s Strategic Investment Boost
TheFlyEdesa Biotech founder Par Nijhawan to invest up to $5M in company
TipRanks Canadian Auto-Generated NewsdeskEdesa Biotech to Present at Global Conferences
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App